MedTrace Logo

Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency

NCT06497829 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-07-12

No results posted yet for this study

Summary

Mevalonate kinase deficiency (HyperIgD syndrome, HIDS) is an inborn error of immunity caused by a block in the mevalonate pathway. The subsequent lack of isoprenoids with antiinflammatory properties might contribute to the autoinflammatory nature of the disease.

A pilot study aims to verify the safety and efficacy of the dietary supplement Geranylgeraniol, aiming at a mitigation of isoprenoids deficiency caused by the above-mentioned block in the MVK pathway.

Conditions

  • Mevalonate Kinase Deficiency

Interventions

DIETARY_SUPPLEMENT

geranylgeraniol

GG Pure (Extendlife Natural Products) containing GG gold®30 Annatto Extract, 500 mg capsule, use for 3 months, once daily

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • University Hospital, Motol

    lead OTHER

Principal Investigators

  • Anna Šedivá, Mgr · University Hospital, Motol

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-25
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06497829 on ClinicalTrials.gov